OncoMatch/Clinical Trials/NCT05641935

Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

Is NCT05641935 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Sulfur Hexafluoride Lipid Microspheres for recurrent renal cell carcinoma.

Phase 2Recruitingjohn eisenbreyNCT05641935Data as of May 2026

Treatment: Sulfur Hexafluoride Lipid Microspheres — This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.

Check if I qualify

Extracted eligibility criteria

Cancer type

Renal Cell Carcinoma

Prior therapy

Must have received:

Previously received cryotherapy or microwave therapy of RCC

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Sidney Kimmel Cancer Center at Thomas Jefferson University · Philadelphia, Pennsylvania

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify